Identification of blood lipid markers of docetaxel treatment in prostate cancer patients

Abstract Docetaxel is commonly used for treatment of castration-resistant prostate cancer. Unfortunately, many prostate cancer patients develop resistance to docetaxel. Clinical markers less invasive than biopsies, such as blood samples, would be ideal for monitoring and predicting patient treatment...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Morgan C. Finnerty, Franklin E. Leach, Yousef Zakharia, Kenneth G. Nepple, Michael G. Bartlett, Michael D. Henry, Brian S. Cummings
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2024-09-01
coleção:	Scientific Reports
Assuntos:	Docetaxel Prostate cancer Lipidomics Drug resistance Biomarker Clinical
Acesso em linha:	https://doi.org/10.1038/s41598-024-73074-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!